Family Medicine Doctors in N Ogden, UT Accepting Medicare
3 Family Medicine doctors found. Showing 1 - 3
 Dr. Frank H Brown, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 N Washington Blvd, N Ogden, UT 84414 Phone: 801-786-7500 Fax: 801-786-7555 |
Dr. C Preston Allen, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 North Washington Blvd, N Ogden, UT 84414 Phone: 801-786-7500 |
Dr. Steven W Wynn, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 North Washington Blvd, N Ogden, UT 84414 Phone: 801-387-8300 |
News Archive
FedMed gains access to Trovagene's Precision Cancer Monitoring tests and service
Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that it has entered into an agreement with FedMed, Inc. establishing health benefit access to Trovagene's full line of Precision Cancer Monitoring (PCM) tests and services.
Researchers identify how molecules of microRNA are responsible for the growth of blood vessels in a model for human colon cancer
The process, called angiogenesis, results in ability of ravenous cancer cells to recruit blood vessels and receive a steady supply of nutrients and oxygen.
Combination therapy disables PI3K/Akt/mTOR pathway and induces apoptosis in carcinoid syndrome
Oncotarget published "Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis" which reported that microscopic imaging, immunocytochemistry, wound healing assay, caspase-cleaved cytokeratin 18 CytoDeath ELISA assay, immunofluorescence labeling assays for apoptosis, hypoxia, Western Blotting, Tunnel assay, measurement of 5-HT secretion by carbon fiber amperometry assay, quantitative methylation-specific PCR, morphologic changes, cell viability, apoptosis activity and the expression levels of phospho-Akt1, Akt1, HIF-1α, PI3K, p21, CAIX, 5-HT, phospho-mTOR, and mTOR in xenografts derived from typical H727 and atypical H720 BC cell lines.
Combination of bortezomib and panobinostat shows promise against advanced MM
When the targeted drug bortezomib stops working in patients with advanced multiple myeloma, the patients survive only an average of five months longer. But a phase 2 clinical trial has shown that pairing bortezomib with an experimental drug, panobinostat, may be a promising new treatment for such patients, Dana-Farber Cancer Institute researchers say.
New test successfully identifies arrhythmogenic right ventricular cardiomyopathy
A study led by investigators at Beth Israel Deaconess Medical Center (BIDMC) has demonstrated that a new immunohistochemical test is reliable in diagnosing a dangerous arrhythmic heart disease known as arrhythmogenic right ventricular cardiomyopathy (ARVC.) Reported in the March 12 issue of The New England Journal of Medicine ( NEJM ), the new findings offer the possibility of a highly sensitive and specific means of identifying this life- threatening condition at an early stage, when it can be treated with by implanting a cardiac defibrillator.
› Verified 6 days ago